Chemours Co-The

Market Summary

USD28.72-0.86

Market Closed

-2.91%

CC Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)

CC Stock Price

View Fullscreen

CC RSI Chart

CC Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)

CC Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

-14.25

Price/Sales (Trailing)

0.73

EV/EBITDA

19.02

Price/Free Cashflow

-62.72

CC Price/Sales (Trailing)

CC Profitability

EBT Margin

-5.10%

Return on Equity

-40.69%

Return on Assets

-3.88%

Free Cashflow Yield

-1.59%

CC Fundamentals

CC Revenue

Revenue (TTM)

6.0B

Revenue Y/Y

-16.32%

Revenue Q/Q

-9.49%

CC Earnings

Earnings (TTM)

-308.0M

Earnings Y/Y

-91.67%

Earnings Q/Q

105.32%

Price Action

Last 7 days

13.0%

Last 30 days

15.2%

Last 90 days

-11.9%

Trailing 12 Months

-5.7%

How does CC drawdown profile look like?

CC Financial Health

Current Ratio

1.68

CC Investor Care

Dividend Yield

3.38%

Dividend/Share (TTM)

Buy Backs (1Y)

3.08%

Diluted EPS (TTM)

-1.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.6B	6.3B	6.0B	0
2022	6.7B	6.9B	7.0B	6.8B
2021	5.1B	5.7B	6.1B	6.3B
2020	5.5B	5.1B	5.0B	5.0B
2019	6.3B	5.9B	5.6B	5.5B
2018	6.5B	6.7B	6.7B	6.6B
2017	5.5B	5.7B	5.9B	6.2B
2016	5.7B	5.5B	5.4B	5.4B
2015	6.2B	6.1B	5.9B	5.7B
2014	6.8B	6.6B	6.5B	6.4B
2013	0	0	0	6.9B

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for CC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 02, 2023	charles ron christopher	sold (taxes)	-62,248	24.44	-2,547	senior vice president, people
Aug 01, 2023	dignam denise	acquired	-	-	2,712	svp, president, titanium techn
Aug 01, 2023	lock jonathan	acquired	-	-	9,224	svp, chief development officer
Aug 01, 2023	abbott matthew s	acquired	-	-	4,069	svp, chief enterprise transfor
Aug 01, 2023	familiar calderon gerardo	acquired	-	-	7,867	pres advanced performance mat
Aug 01, 2023	wellman kristine m	acquired	-	-	3,255	svp, gc & corp. secretary
Aug 01, 2023	wisel camela	acquired	-	-	5,425	vp, cao & controller
Aug 01, 2023	scarborough alvenia	acquired	-	-	6,782	svp corp communications & cbo
Aug 01, 2023	martinko joseph t.	acquired	-	-	5,154	president, thermal & specializ
Jun 09, 2023	newman mark	bought	249,978	32.6299	7,661	president and ceo

Which funds bought or sold CC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 01, 2023	B. Riley Wealth Advisors, Inc.	sold off	-100	-773,643	-	-%
Nov 30, 2023	Modera Wealth Management, LLC	unchanged	-	-93,237	295,843	0.01%
Nov 28, 2023	Dakota Community Bank & Trust NA	sold off	-100	-11,657	-	-%
Nov 27, 2023	AllSquare Wealth Management LLC	unchanged	-	18.00	1,459	-%
Nov 27, 2023	TRUST CO OF VERMONT	added	20.13	-1,903	20,084	-%
Nov 24, 2023	DEUTSCHE BANK AG\	added	4,407	47,911,900	49,351,700	0.03%
Nov 22, 2023	Aurora Investment Counsel	added	24.7	-22,863	418,563	0.28%
Nov 21, 2023	Invst, LLC	added	3.38	-176,035	646,833	0.09%
Nov 21, 2023	Walleye Capital LLC	new	-	559,822	559,822	-%
Nov 21, 2023	TOMPKINS FINANCIAL CORP	unchanged	-	-2,334	7,405	-%

Latest Funds Activity

Are funds buying CC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CC

No. of Funds

Schedule 13G FIlings of Chemours Co-The

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	sessa capital (master), l.p.	0.36%	547,057	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	12.20%	18,416,153	SC 13G/A
Jan 26, 2023	blackrock inc.	12.3%	18,516,903	SC 13G/A
Jan 20, 2023	blackrock inc.	12.3%	18,516,903	SC 13G/A
Apr 08, 2022	blackrock inc.	11.3%	18,075,740	SC 13G/A
Feb 14, 2022	sessa capital (master), l.p.	3.6%	5,748,120	SC 13G/A
Feb 09, 2022	vanguard group inc	9.98%	16,258,762	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Chemours Co-The

View All Filings

Date Filed	Form Type	Document
Dec 04, 2023	3	Insider Trading
Nov 29, 2023	8-K	Current Report
Nov 22, 2023	8-K	Current Report
Nov 06, 2023	4	Insider Trading
Oct 27, 2023	10-Q	Quarterly Report
Oct 26, 2023	8-K	Current Report
Oct 03, 2023	4	Insider Trading
Oct 03, 2023	4	Insider Trading
Oct 03, 2023	3	Insider Trading
Sep 14, 2023	144	Notice of Insider Sale Intent

CC Fair Value

Peers (Alternatives to Chemours Co-The)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
APD	60.0B	12.6B	-7.90%	-15.20%	26.1	4.76	-0.78%	1.95%
DOW	36.7B	45.9B	4.77%	2.31%	26.87	0.8	-22.80%	-76.46%
CE	15.4B	10.7B	16.84%	30.28%	7.58	1.44	11.66%	22.90%
AVTR	14.5B	7.0B	16.77%	-5.67%	39.82	2.06	-7.68%	-42.97%
ALB	14.1B	9.9B	-6.31%	-57.68%	4.23	1.42	76.68%	113.94%
MID-CAP
EMN	10.0B	9.4B	10.15%	-3.05%	12.61	0.94	-13.99%	-50.00%
CBT	4.3B	3.9B	14.58%	3.71%	9.46	1.09	-9.03%	109.45%
BCPC	4.1B	926.3M	4.56%	-10.31%	39.49	4.4	0.36%	-5.15%
AVNT	3.2B	3.2B	4.15%	-0.73%	5.44	1	5.04%	214.53%
ARCH	3.0B	3.2B	10.84%	8.58%	3.71	0.94	-11.97%	-23.95%
SMALL-CAP
CCF	1.2B	404.0M	0.66%	31.83%	36.23	2.98	24.06%	-25.72%
ASIX	736.4M	1.6B	5.26%	-33.56%	7.89	0.47	-20.87%	-42.34%
CMT	155.0M	370.4M	-29.97%	67.32%	6.75	0.42	1.73%	194.09%
AREC	113.7M	21.4M	21.58%	17.36%	13.56	5.32	-45.68%	139.96%
AMRS	14.7M	268.2M	-95.00%	-99.56%	-0.02	0.05	20.46%	-590.95%

Chemours Co-The News

Latest updates

Financials for Chemours Co-The

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-9.5%	1,487	1,643	1,536	1,338	1,777	1,915	1,764	1,575	1,680	1,655	1,436	1,338	1,233	1,093	1,305	1,353	1,390	1,408	1,376	1,464	1,628
Gross Profit	-31.5%	281	410	368	202	432	497	486	393	427	264	297	313	257	199	298	150	294	323	296	400	477
Operating Expenses	-60.7%	317	806	166	211	171	280	182	190	154	204	158	250	143	147	160	183	184	162	186	229	195
S&GA Expenses	-78.8%	165	779	124	175	140	254	141	158	124	172	139	180	112	110	125	126	130	136	156	191	163
R&D Expenses	0%	28.00	28.00	26.00	31.00	32.00	25.00	30.00	29.00	27.00	27.00	24.00	27.00	22.00	20.00	24.00	19.00	20.00	19.00	22.00	22.00	20.00
EBITDA Margin	-56.1%	0.03*	0.07*	0.17*	0.18*	0.22*	0.22*	0.20*	0.19*	0.15*	0.13*	0.14*	0.14*	0.03*	0.01*	0.01*	-	-	-	-	-	-
Interest Expenses	14.6%	55.00	48.00	42.00	41.00	41.00	40.00	41.00	44.00	45.00	47.00	49.00	50.00	53.00	53.00	54.00	52.00	53.00	52.00	51.00	343	-47.00
Income Taxes	105.3%	3.00	-57.00	28.00	28.00	59.00	30.00	46.00	69.00	17.00	-22.00	5.00	4.00	-16.00	-4.00	-23.00	-137	15.00	37.00	13.00	40.00	-6.00
Earnings Before Taxes	105.3%	23.00	-433	173	-69.00	299	231	280	301	231	44.00	101	23.00	60.00	20.00	77.00	-454	91.00	133	107	182	269
EBT Margin	-969.4%	-0.05*	0.00*	0.10*	0.11*	0.16*	0.15*	0.13*	0.11*	0.07*	0.04*	0.04*	0.04*	-0.06*	-0.05*	-0.03*	-	-	-	-	-	-
Net Income	105.3%	20.00	-376	145	-97.00	240	201	234	233	214	66.00	96.00	19.00	76.00	24.00	100	-317	76.00	96.00	94.00	142	275
Net Income Margin	-266.9%	-0.05*	-0.01*	0.07*	0.09*	0.13*	0.13*	0.11*	0.10*	0.06*	0.05*	0.04*	0.04*	-0.02*	-0.02*	-0.01*	-	-	-	-	-	-
Free Cashflow	1366.7%	44.00	3.00	-210	93.00	229	229	-104	131	244	189	-21.00	300	252	50.00	-62.00	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	3.8%	7,948	7,660	7,624	7,640	7,745	7,730	7,524	7,550	7,530	7,479	7,170	7,082	6,948	7,034	6,948	7,258	7,456	7,433	7,325	7,362	7,512
Current Assets	9.2%	3,683	3,374	3,202	3,214	3,543	3,606	3,393	3,345	3,371	3,047	2,786	2,633	2,605	2,717	2,591	2,777	2,827	2,832	2,847	3,293	3,448
Cash Equivalents	15.4%	852	738	816	1,102	1,368	1,348	1,245	1,551	1,131	1,139	1,008	1,105	956	1,031	714	943	694	630	697	1,201	1,275
Inventory	-9.1%	1,314	1,446	1,486	1,404	1,321	1,219	1,166	1,099	1,016	1,046	988	939	993	1,074	1,114	1,079	1,223	1,250	1,218	1,147	1,086
Net PPE	-2.2%	3,119	3,190	3,180	3,171	3,071	3,111	3,131	3,154	3,127	3,448	3,432	3,474	3,418	3,423	3,444	3,559	3,520	3,491	3,379	3,291	3,207
Goodwill	0%	102	102	102	102	102	102	102	102	102	153	152	153	-	-	-	153	-	-	-	-2.00	-
Liabilities	5.0%	7,191	6,850	6,396	6,533	6,460	6,515	6,357	6,468	6,531	6,579	6,318	6,267	6,214	6,375	6,287	6,563	6,613	6,604	6,509	6,342	6,366
Current Liabilities	0.2%	2,195	2,190	1,745	1,891	1,951	1,886	1,775	1,858	1,779	1,674	1,501	1,442	1,308	1,156	1,343	1,541	1,643	1,448	1,572	1,709	1,698
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	13.00	13.00	14.00
LT Debt, Non Current	9.4%	3,944	3,604	3,599	3,590	3,510	3,656	3,692	3,724	3,829	3,964	3,970	4,005	4,063	4,327	4,012	4,026	4,007	4,190	3,965	3,959	3,985
Shareholder's Equity	-6.8%	755	810	1,228	1,107	1,285	1,215	1,167	1,082	999	900	852	815	734	659	661	695	843	829	816	1,020	1,146
Retained Earnings	-1.0%	1,845	1,864	2,278	2,170	2,304	2,102	1,940	1,746	1,554	1,381	1,357	1,303	1,325	1,290	1,308	1,249	1,606	1,571	1,517	1,466	1,358
Additional Paid-In Capital	1.6%	1,030	1,014	1,004	1,016	1,015	1,005	956	944	926	920	907	890	879	872	870	859	857	853	845	860	856
Accumulated Depreciation	-3.7%	6,124	6,358	6,319	6,216	6,115	6,153	6,123	6,078	6,080	6,220	6,121	6,108	5,973	5,873	5,770	5,854	5,754	5,768	5,710	5,701	5,678
Shares Outstanding	0.1%	148	148	149	149	153	156	157	161	164	165	165	165	164	164	164	164	163	163	165	171	174
Minority Interest	0%	2.00	2.00	1.00	-	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	113.1%	130,000	61,000	-119,000	160,000	301,000	291,000	2,000	214,000	311,000	256,000	39,000	353,000	299,000	111,000	44,000	400,000	288,000	6,000	-44,000	259,000	342,000
Share Based Compensation	100.0%	6,000	3,000	4,000	3,000	7,000	7,000	10,000	10,000	4,000	8,000	12,000	4,000	3,000	1,000	8,000	1,000	4,000	6,000	8,000	4,000	5,000
Cashflow From Investing	196.7%	58,000	-60,000	-97,000	-65,000	-74,000	-35,000	-110,000	422,000	-68,000	-57,000	-77,000	-34,000	-37,000	-51,000	-112,000	-96,000	-131,000	-122,000	-134,000	-160,000	-97,000
Cashflow From Financing	545.2%	325,000	-73,000	-73,000	-190,000	-175,000	-131,000	-189,000	-201,000	-241,000	-76,000	-42,000	-187,000	-354,000	247,000	-155,000	-59,000	-77,000	41,000	-324,000	-170,000	-182,000
Dividend Payments	-2.6%	37,000	38,000	37,000	37,000	39,000	38,000	40,000	41,000	41,000	41,000	41,000	41,000	41,000	41,000	41,000	40,000	41,000	41,000	42,000	42,000	45,000
Buy Backs	-51.4%	18,000	37,000	14,000	144,000	79,000	128,000	144,000	93,000	67,000	13,000	-	-	-	-	-	-	-	67,000	255,000	124,000	126,000

CC Income Statement

2023-09-30

Interim Consolidated Statements of Operations (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 1,487	$ 1,777	$ 4,666	$ 5,456
Cost of goods sold	1,206	1,345	3,607	4,042
Gross profit	281	432	1,059	1,414
Selling, general, and administrative expense	165	140	1,067	535
Research and development expense	28	32	82	88
Restructuring, asset-related, and other charges	124	(1)	139	10
Total other operating expenses	317	171	1,288	633
Equity in earnings of affiliates	13	16	38	44
Interest expense, net	(55)	(41)	(145)	(123)
(Loss) gain on extinguishment of debt	(1)	7	(1)	7
Other income, net	102	56	100	101
Income (loss) before income taxes	23	299	(237)	810
Provision for (benefit from) income taxes	3	59	(26)	135
Net income (loss)	20	240	(211)	675
Less: Net income attributable to non-controlling interests			1
Net income (loss) attributable to Chemours	$ 20	$ 240	$ (212)	$ 675
Per share data
Basic earnings (loss) per share of common stock	$ 0.13	$ 1.54	$ (1.42)	$ 4.3
Diluted earnings (loss) per share of common stock	$ 0.13	$ 1.52	$ (1.42)	$ 4.21

CC Balance Sheet

2023-09-30

Interim Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 852	$ 1,102
Restricted cash and restricted cash equivalents	595
Accounts and notes receivable, net	846	626
Inventories	1,314	1,404
Prepaid expenses and other	76	82
Total current assets	3,683	3,214
Property, plant, and equipment	9,243	9,387
Less: Accumulated depreciation	(6,124)	(6,216)
Property, plant, and equipment, net	3,119	3,171
Operating lease right-of-use assets	258	240
Goodwill	102	102
Other intangible assets, net	5	13
Investments in affiliates	192	175
Restricted cash and restricted cash equivalents		202
Other assets	589	523
Total assets	7,948	7,640
Current liabilities:
Accounts payable	901	1,251
Compensation and other employee-related cost	94	121
Short-term and current maturities of long-term debt	23	25
Current environmental remediation	138	194
Other accrued liabilities	1,039	300
Total current liabilities	2,195	1,891
Long-term debt, net	3,944	3,590
Operating lease liabilities	207	198
Long-term environmental remediation	467	474
Deferred income taxes	54	61
Other liabilities	324	319
Total liabilities	7,191	6,533
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 197,344,369 shares issued and 148,364,181 shares outstanding at September 30, 2023; 195,375,810 shares issued and 148,504,030 shares outstanding at December 31, 2022)	2	2
Treasury stock, at cost (48,980,188 shares at September 30, 2023; 46,871,780 shares at December 31, 2022)	(1,807)	(1,738)
Additional paid-in capital	1,030	1,016
Retained earnings	1,845	2,170
Accumulated other comprehensive loss	(315)	(343)
Total Chemours stockholders’ equity	755	1,107
Non-controlling interests	2
Total equity	757	1,107
Total liabilities and equity	$ 7,948	$ 7,640

About Chemours Co-The

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and other applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.

CEO	Mr. Mark E. Newman
WEBSITE	www.chemours.com
EMPLOYEES	6600

Chemours Co-The Frequently Asked Questions

What is the ticker symbol for Chemours Co-The? What does CC stand for in stocks?

CC is the stock ticker symbol of Chemours Co-The. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Chemours Co-The (CC)?

As of Mon Dec 04 2023, market cap of Chemours Co-The is 4.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CC stock?

You can check CC's fair value in chart. The fair value of Chemours Co-The is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Chemours Co-The is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Chemours Co-The a good stock to buy?

The fair value guage provides a quick view whether CC is over valued or under valued. Whether Chemours Co-The is cheap or expensive depends on the assumptions which impact Chemours Co-The's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CC.

What is Chemours Co-The's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 04 2023, CC's PE ratio (Price to Earnings) is -14.25 and Price to Sales (PS) ratio is 0.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CC PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

CC Alerts

CC Stock Price

CC RSI Chart

CC Alerts

CC Valuation

CC Price/Sales (Trailing)

CC Profitability

CC Fundamentals

CC Revenue

CC Earnings

Price Action

How does CC drawdown profile look like?

CC Financial Health

CC Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for CC

Which funds bought or sold CC recently?

Latest Funds Activity

Schedule 13G FIlings of Chemours Co-The

Recent SEC filings of Chemours Co-The

CC Fair Value

Peers (Alternatives to Chemours Co-The)

Chemours Co-The News

Financials for Chemours Co-The

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

CC Income Statement

CC Balance Sheet

About Chemours Co-The

Chemours Co-The Frequently Asked Questions

What is the ticker symbol for Chemours Co-The? What does CC stand for in stocks?

What is the market capital of Chemours Co-The (CC)?

What is the fair value of CC stock?

Is Chemours Co-The a good stock to buy?

What is Chemours Co-The's Price to Earnings (PE) and Price to sales (PS) ratio?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)